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Eﬀ ect of dronabinol on progression in progressive multiple 
sclerosis (CUPID): a randomised, placebo-controlled trial
John Zajicek, Susan Ball, David Wright, Jane Vickery, Andrew Nunn, David Miller, Mayam Gomez Cano, David McManus, Sharukh Mallik, 
Jeremy Hobart, on behalf of the CUPID investigator group
Summary
Background Laboratory evidence has shown that cannabinoids might have a neuroprotective action. We investigated 
whether oral dronabinol (Δ⁹-tetrahydrocannabinol) might slow the course of progressive multiple sclerosis.
Methods In this multicentre, parallel, randomised, double-blind, placebo-controlled study, we recruited patients aged 
18–65 years with primary or secondary progressive multiple sclerosis from 27 UK neurology or rehabilitation 
departments. Patients were randomly assigned (2:1) to receive dronabinol or placebo for 36 months; randomisation 
was by stochastic minimisation, using a computer-generated randomisation sequence, balanced according to 
expanded disability status scale (EDSS) score, centre, and disease type. Maximum dose was 28 mg per day, titrated 
against bodyweight and adverse eﬀ ects. Primary outcomes were EDSS score progression (masked assessor, time to 
progression of ≥1 point from a baseline score of 4·0–5·0 or ≥0·5 points from a baseline score of ≥5·5, conﬁ rmed after 
6 months) and change from baseline in the physical impact subscale of the 29-item multiple sclerosis impact scale 
(MSIS-29-PHYS). All patients who received at least one dose of study drug were included in the intention-to-treat 
analyses. This trial is registered as an International Standard Randomised Controlled Trial (ISRCTN 62942668).
Findings Of the 498 patients randomly assigned to a treatment group, 329 received at least one dose of dronabinol and 
164 received at least one dose of placebo (ﬁ ve did not receive the allocated intervention). 145 patients in the dronabinol 
group had EDSS score progression (0·24 ﬁ rst progression events per patient-year; crude rate) compared with 73 in 
the placebo group (0·23 ﬁ rst progression events per patient-year; crude rate); HR for prespeciﬁ ed primary analysis 
was 0·92 (95% CI 0·68–1·23; p=0·57). Mean yearly change in MSIS-29-PHYS score was 0·62 points (SD 3·29) in the 
dronabinol group versus 1·03 points (3·74) in the placebo group. Primary analysis with a multilevel model gave an 
estimated between-group diﬀ erence (dronabinol–placebo) of –0·9 points (95% CI –2·0 to 0·2). We noted no serious 
safety concerns (114 [35%] patients in the dronabinol group had at least one serious adverse event, compared with 
46 [28%] in the placebo group).
Interpretation Our results show that dronabinol has no overall eﬀ ect on the progression of multiple sclerosis in the 
progressive phase. The ﬁ ndings have implications for the design of future studies of progressive multiple sclerosis, 
because lower than expected progression rates might have aﬀ ected our ability to detect clinical change.
Funding UK Medical Research Council, National Institute for Health Research Eﬃ  cacy and Mechanism Evaluation 
programme, Multiple Sclerosis Society, and Multiple Sclerosis Trust.
Introduction
Multiple sclerosis is the most common cause of neuro-
logical disability in young adults. It is generally regarded 
as an autoimmune disease, with early episodes of inﬂ am-
mation associated with axonal damage, which becomes 
the major pathological process as the disease progresses. 
Initial clinical relapses are often replaced by secondary 
gradual progression after several years. Al though 
therapies for the inﬂ ammatory phase are available, none 
has been shown to slow disease progression in the 
absence of relapses. 
Cannabinoids are used to ameliorate multiple-
sclerosis-related symptoms, particularly muscle 
spasticity and pain. Our previous large multicentre 
cannabinoids in multiple sclerosis (CAMS) trial1 
focused on testing symptomatic beneﬁ ts of oral 
cannabinoids for 15 weeks in 630 participants, 95% 
with progressive disease. A treatment eﬀ ect on 
spasticity (primary outcome assessed by the Ashworth 
scale) was not evident, although more participants 
reported beneﬁ ts from symptom alleviation in the 
active group than in the placebo group. During the 
study, experimental evidence emerged to suggest that 
cannabinoids have neuroprotective eﬀ ects (with 
antioxidant,2 antiapoptotic,3 antiexcitatory,4 and anti-
inﬂ ammatory actions5) and might also encourage 
remyelination.6 The CAMS follow-up study,7 in which 
participants, masked to treatment, could opt to continue 
study drug for up to 12 months, reported signiﬁ cant 
eﬀ ects on spasticity in the dronabinol 
(Δ⁹-tetrahydrocannabinol) group, with some evidence 
for an eﬀ ect on disability, measured by the expanded 
disability status scale (EDSS) and the Rivermead 
mobility index (RMI). This ﬁ nding provided clinical 
evidence to support experimental data suggesting that 
cannabinoids might have a neuroprotective eﬀ ect in 
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progressive multiple sclerosis, and conﬁ rmed that this 
treatment continued to ameliorate patients’ symptoms 
for up to 12 months.
In the cannabinoid use in progressive inﬂ ammatory 
brain disease (CUPID) trial, we aimed to test the 
hypothesis that oral dronabinol will slow progression of 
primary and secondary progressive multiple sclerosis 
over 3 years.
Methods
Study design and participants
We undertook a randomised, double-blind, placebo-
controlled, parallel-group study. Patients were 
prospectively enrolled at 27 UK neurology or 
rehabilitation outpatient centres. Final follow-up data 
collection took place in January, 2012. Eligible patients 
were aged 18–65 years with a diagnosis of multiple 
sclerosis,8 either a primary progressive or a secondary 
progressive disease course, evidence of disease 
progression in the preceding year in the opinion of the 
local neurologist, an EDSS score of 4·0–6·5 at baseline, 
and willingness to abstain from other cannabis use 
during the trial. Exclusion criteria included use of 
immunomodulatory or otherwise potentially disease-
modifying therapies in the previous 12 months, 
systemic corticosteroid use in the previous 3 months, 
predominant relapsing-remitting disease in the 
previous 12 months, multiple sclerosis relapse in the 
previous 6 months that was likely to have aﬀ ected 
patients’ EDSS scores, history of previous psychosis or 
other serious medical illness, pregnancy, serious 
cognitive impairment (such that the patient was unable 
to provide informed consent), and cannabinoid use 
within the previous 4 weeks (a urinary cannabinoid test 
was done before study entry). The study was approved 
by the South and West Devon Research Ethics 
Committee and done in accordance with Good Clinical 
Practice guidelines. Eligible patients provided written 
informed consent before participation.
Randomisation and masking
Participants were assigned via computer-generated 
randomisation to receive oral dronabinol in hard 
gelatine capsules or identically matched (in terms of 
appearance and smell) placebo vegetable oil capsules for 
36 months in a 2:1 active-to-placebo ratio (to encourage 
recruitment and retention). The ran domisation 
allocation sequence, generated by an independent 
statistician using a stochastic minimisation algorithm, 
was balanced according to EDSS score, centre, and 
disease type (primary or secondary progressive multiple 
sclerosis) with a random component. Assignment of 
treatment was undertaken by the central pharmacy 
independently of the research team to ensure allocation 
concealment. Participants and all other personnel 
directly involved in the study were masked to treatment 
allocation.
Procedures
Medical history, concomitant medication record, EDSS 
score, and consent were obtained at a screening visit. 
Dronabinol or placebo was provided at baseline 2–4 weeks 
later, after conﬁ rmation of eligibility and randomisation. 
Because of the large interindividual dose variation with 
oral cannabinoids, a 4 week titration period was included 
for both study groups, during which doses were adjusted 
to an appropriate level for each participant according to 
bodyweight and adverse events (AEs). Starting dose was 
one capsule (3·5 mg Δ⁹-tetrahydrocannabinol equivalent) 
twice daily. The maximum dose was 28 mg per day. 
Participants were instructed to increase their twice-daily 
dose by one capsule at weekly intervals to a maximum 
weight-related dose (table 1). If adverse eﬀ ects developed, 
participants were advised not to increase the dose; if 
unwanted side-eﬀ ects were intolerable, the dose was 
reduced. Dronabinol and placebo were supplied by Insys 
Therapeutics (Phoenix, AZ, USA) and distributed to sites 
by a central pharmacy.
Our study had two primary outcomes: time to EDSS 
score progression  of at least 1 point from a baseline 
EDSS score of 4·0, 4·5, or 5·0 or at least 0·5 points from 
a baseline EDSS score of 5·5 or greater, conﬁ rmed by a 
physician at the next scheduled 6 monthly visit; and 
change from baseline to end of study in the physical 
impact subscale of the patient-reported 29-item multiple 
sclerosis impact scale (MSIS-29-PHYS). Secondary 
outcomes included assessment of number and nature of 
AEs, multiple sclerosis functional composite (MSFC) 
Z score change from baseline to ﬁ nal visit, multiple 
sclerosis walking scale (MSWS-12), and RMI.
Participants were reviewed after 2 and 4 weeks from 
when they began taking the study drug for AE monitoring 
and dose adjustment. Assessment visits were held at 
3 and 6 months, and then every 6 months up to 36 months 
(visit 11) before study medication was reduced by one 
capsule per twice-daily dose each week (maximum period 
of reduction was 4 weeks). Participants who had new 
EDSS score progression according to the deﬁ ned study 
endpoint at 36 months attended a further visit at 
42 months (visit 12) to conﬁ rm EDSS score progression 
or otherwise, before discontinuing trial medication.
Each study site had a treating physician, responsible 
for dose adjustment and AE monitoring, and a trained 
assessing physician, responsible for 6-monthly EDSS 
assessment, but masked to AEs. The option of validated 
telephone EDSS assessment for participants unable or 
unwilling to attend clinic was introduced from June, 
2010, to improve data completeness. The MSFC 
(consisting of a timed 25 foot walk, paced auditory serial 
addition test, and a nine hole peg test) was assessed 
yearly by a non-physician, providing training had been 
given. RMI was assessed every 6 months. The MSIS-29-
PHYS and MSWS-12 were completed by participants 
every 6 months. Safety monitoring included standard 
clinical laboratory assessments (chemistry and 
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haematology) at regular intervals. Random urine 
testing, used to detect cannabinoid use in the placebo 
group, was done in both groups to avoid unblinding. 
Brain MRI was done at baseline and yearly in 
participants who were chosen on the basis of quality 
and cost of MRI at their local centre. Images were 
analysed for percentage brain volume change (PBVC)9,10 
and new and enlarging lesions at the Queen Square MS 
Centre, Nuclear Magnetic Resonance Research Unit, 
Institute of Neurology, University College London 
(London, UK).
A trial steering committee including an independent 
chairman, neurologist, statistician, and lay 
representative were responsible for trial oversight and 
met on a yearly basis. An independent data monitoring 
committee (IDMC) met yearly to review unblinded 
safety and eﬃ  cacy data. Interim analyses of primary 
outcomes were produced by an independent statistician 
on request from the IDMC, with the predeﬁ ned 
Haybittle-Peto boundary stopping rule. Four interim 
analyses were undertaken after 298 and 493 participants 
had been recruited and then yearly during follow-up. 
The IDMC recommended continuation of the trial after 
all interim analyses.
Statistical analysis
Previous data suggested a probable progression rate of 
about 70% in the control (placebo) group.11 On the basis 
of this progression rate and an expected 5% yearly loss to 
follow-up rate, recruitment of 492 patients would provide 
90% power to detect a one-third reduction in hazard of 
progression (ie, hazard ratio [HR] of 0·67), corresponding 
to a relative reduction in risk of progression over 3 years 
of 21% (from 70% to 55% progression in the dronabinol 
group). For MRI eﬀ ects, 261 patients allocated to 
dronabinol and placebo in a 2:1 ratio would provide 90% 
power to detect a 40% reduction in the rate of atrophy 
over 3 years.
Data analysis, using statistical software R 
(version 2.14.1),12 was by intention to treat, undertaken 
in accordance with a prespeciﬁ ed analysis plan, ﬁ nalised 
and agreed by the trial steering committee before 
unmasking. We did all tests at the 5% signiﬁ cance level, 
with no adjustments for multiple testing. In models for 
each outcome, we considered main eﬀ ects of centre, 
baseline EDSS score, disease type, age at registration, 
sex, and weight, as well as treatment.
We used Kaplan-Meier estimates to show probability 
of EDSS score progression in the two treatment groups 
and a Cox proportional hazards model to analyse time to 
progression. We also estimated HRs for subgroups 
deﬁ ned by sex, baseline EDSS score, disease type, 
weight, and age.
The primary analysis was based on EDSS data obtained 
according to trial schedule; we regarded losses to 
follow-up before conﬁ rmed progression as missing data 
and treated them as censored observations at the time of 
last visit at which EDSS measurements were taken. 
Sensitivity of conclusions was assessed by repeating the 
analyses, treating losses to follow-up before conﬁ rmed 
progression as progression events.
We calculated total MSIS-29-PHYS scores and scores 
for each MSFC component with previously published 
Week 1 Week 2 Week 3 Week 4 to study 
end
<60 kg 1 twice a day 2 twice a day 2 twice a day 2 twice a day
60–80 kg 1 twice a day 2 twice a day 3 twice a day 3 twice a day
>80 kg 1 twice a day 2 twice a day 3 twice a day 4 twice a day
Table 1: Number of capsules prescribed according to weight of 
participants at baseline
Dronabinol 
(n=329)
Placebo 
(n=164)
All
(n=493)
Age (years) 52·29 (7·6) 51·97 (8·2) 52·19 (7·8)
Weight (kg) 74·54 (16·5) 75·93 (16·5) 75 (16·5)
Men 133 (40%) 68 (41%) 201 (41%)
Women 196 (60%) 96 (59%) 292 (59%)
Primary progressive MS 126 (38%) 65 (40%) 191 (39%)
Secondary progressive MS 203 (62%) 99 (60%) 302 (61%)
EDSS score* (n per score)
4 20 (6%) 9 (5%) 29 (6%)
4·5 18 (5%) 7 (4%) 25 (5%)
5 22 (7%) 10 (6%) 32 (6%)
5·5 16 (5%) 8 (5%) 24 (5%)
6 169 (51%) 85 (52%) 254 (52%)
6·5 84 (26%) 45 (27%) 129 (26%)
EDSS score* 5·8 (0·69) 5·9 (0·67) 5·9 (0·69)
MSFC components†
T25-FW
Time (s)‡ 20·34 (30·2) 15·25 (13·4) 18·64 (25·9)
Speed (feet per s)§ 2·22 (1·21) 2·3 (1·17) 2·25 (1·19)
Not reported 4 (1·2%) 1 (0·6%) 5 (1·0%)
9-HPT score¶ 0·04 (0) 0·03 (0) 0·04 (0)
Not reported 1 (0·3%) 0 1 (0·2%)
PASAT score|| 41·43 (13·8) 41·02 (13·4) 41·29 (13·6)
Not reported 2 (0·6%) 3 (1·8%) 5 (1·0%) 
MSFC composite Z score** –0·099 (0·69) –0·108 (0·62) –0·102 (0·67)
Not reported 8 (2·4%) 5 (3·0%) 13 (2·6%)
MSIS-29-PHYS score†† 55·0 (10·8) 55·2 (11·0) 55·1 (10·8)
Not reported 3 (0·9%) 2 (1·2%) 5 (1·0%)
Data are mean (SD), n (%), and median (IQR). MS=multiple sclerosis. EDSS=expanded disability status scale. 
MSFC=multiple sclerosis functional composite. T25-FW=timed 25 foot walk. 9-HPT=nine hole peg test. PASAT=paced 
auditory serial addition test. MSIS-29-PHYS=29-item multiple sclerosis impact scale, physical impact subscale. *A 
higher score indicates greater disability. †Measured during visit 2 (visit 1 was a practice visit). ‡A longer time indicates 
worse mobility and leg function. §A faster speed indicates greater mobility and leg function. ¶Standard score, 
calculated as the mean of the reciprocal of the mean of the dominant-hand score and the reciprocal of the mean of the 
non-dominant-hand score; a higher score indicates greater ﬁ nger dexterity. ||Standard score, corresponding to the 
number of correctly answered questions out of 60; a higher score indicates greater capacity and rate of information 
processing. **A higher score indicates greater physical and cognitive function. ††Total score, calculated according to 
standard procedure for dealing with missing data, with a possible range from 20 to 80; a higher score indicates a 
greater physical impact of multiple sclerosis.
Table 2: Baseline characteristics of participants by treatment group and overall
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methods.13,14 We computed MSFC component-wise 
Z scores15 using results from all participants at visit 2 as 
reference data.14 We calculated MSFC composite scores 
from the mean of component-wise Z scores and total 
scores for MSWS-1216 and RMI using an algorithm 
analogous to that used for the MSIS-29-PHYS for dealing 
with missing data.
We analysed repeated measures data for MSIS-29-PHYS 
with multilevel models, which included time (visit) and 
the other prespeciﬁ ed covariates. We incorporated 
individual diﬀ erences in scores using random 
coeﬃ  cients.17 Backward elimination was used to identify a 
ﬁ nal, reduced model, including eﬀ ects signiﬁ cant at the 
5% level, and eﬀ ects of time and treatment. Repeated 
measures of MSFC (composite score), MSWS-12 (total 
score), and RMI (total score) were analysed similarly using 
multilevel models, with the same covariates and variable 
selection procedure as for MSIS-29-PHYS.
We used a multilevel model to analyse repeated 
measures data for PBVC from MRI, transformed to 
cumulative, relative PBVC on the log10 scale. We used 
logistic regression models to examine the eﬀ ect of 
treatment and other prespeciﬁ ed covariates on new 
T1 hypointense and new or enlarging T2 hyperintense 
lesions during follow-up. Participants were classiﬁ ed as 
having either no or at least one new or enlarging lesion(s) 
during follow-up. We identiﬁ ed ﬁ nal models with a 
forward selection procedure and included main eﬀ ects 
and interactions signiﬁ cant at the 5% level, as well as the 
main eﬀ ect of treatment.
After prespeciﬁ ed subgroup analyses of time to EDSS 
score progression, in a post-hoc subgroup analysis we 
assessed the eﬀ ect of treatment on time to progression in 
those participants with a baseline EDSS score of 5·5 or 
lower. We used a log-rank test to compare probability of 
progression between treatment groups.
Further post-hoc analyses examined the eﬀ ect of 
treatment in the two participant groups with baseline 
EDSS scores of 5·5 or lower and 6·0–6·5, on both PBVC 
and lesions, by including separate eﬀ ects of treatment in 
these two groups in the models.
We summarised AEs and serious AEs in terms of 
frequencies and relative frequencies. We used Fisher’s 
exact test to test for associations between treatment and 
occurrence of serious AEs and between treatment and 
occurrence of each AE that aﬀ ected at least 10% of all 
participants.
This trial is registered as an International Standard 
Randomised Controlled Trial (ISRCTN 62942668).
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
All authors had full access to all of the data in the study 
and the corresponding author had ﬁ nal responsibility for 
the decision to submit for publication.
Results
We recruited 498 eligible patients between May, 2006, 
and July, 2008. Baseline characteristics were similar in 
both treatment groups (table 2). Of the 493 randomly 
assigned participants who received treatment, 329 were 
assigned to dronabinol and 164 were assigned to placebo. 
415 (84%) completed follow-up, of whom 119 (29%) had 
Figure 1: Trial proﬁ le
PEP=primary endpoint of expanded disability status scale score progression. *Nine patients initially did not fulﬁ l 
entry criteria, but did so on subsequent re-screening.
332 allocated to dronabinol
        329 received allocated intervention
             3 did not receive allocated intervention
                   2 withdrew consent
                   1 ineligible (medical history)
166 allocated to placebo
        164 received allocated intervention
             2 did not receive allocated intervention
                   1 withdrew consent
                   1 uncontrolled hypertension
62 lost to follow-up (6 reached PEP) 16 lost to follow-up (1 reached PEP)
267 completed follow-up (89 oﬀ study 
medication)
     0 excluded from analysis
151 discontinued intervention prematurely
148 completed follow-up (30 oﬀ study 
medication)
     0 excluded from analysis
  46 discontinued intervention prematurely
558 assessed for eligibility (549 unique patients)*
60 excluded 
       45 did not meet inclusion criteria
       10 declined to participate
          3 DNA screening appointment 
          2 uncontrolled hypertension
498 randomly assigned
Dronabinol 
(n=329)
Placebo 
(n=164)
Estimated treatment 
eﬀ ect (95% CI)
p value
First EDSS score progression event, 
number of events (number of ﬁ rst 
progression events per patient-
year*) 
145 (0·24) 73 (0·23) HR 0·92 (0·68 to 1·23)† 0·57
MSIS-29-PHYS score, yearly change 0·62 (3·29) 1·03 (3·74) –0·91 (–2·01 to 0·19)‡ 0·11
MSFC score, yearly change –0·17 (0·28) –0·16 (0·30) –0·03 (–0·19 to 0·09)‡ 0·72
MSWS-12 score, yearly change 0·37 (2·33) 0·52 (2·68) –0·19 (–0·97 to 0·60)‡ 0·74
RMI, yearly change –0·58 (0·96) –0·72 (1·08) 0·04 (–0·24 to 0·32)‡ 0·76
MRI n=182 n=91
PBVC, yearly change –0·68 (0·95) –0·66 (0·98) –0·01% (–0·26 to 0·24)‡ 0·94
New or enlarging T2 lesions 60 (37%) 34 (40%) OR 0·89 (0·50 to 1·58)§ 0·70
New or enlarging T1 lesions 54 (34%) 28 (33%) OR 1·05 (0·59 to 1·88)§ 0·87
Data are n (%) or mean (SD) unless otherwise speciﬁ ed. EDSS=expanded disability status scale. HR=hazard ratio. 
MSIS-29-PHYS=29-item multiple sclerosis impact scale, physical impact subscale. MSFC=multiple sclerosis functional 
composite. MSWS-12=multiple sclerosis walking scale. RMI=Rivermead mobility index. PBVC=percentage brain 
volume change. OR=odds ratio. *Assuming progression events occur at the midpoint of the 6 months between 
follow-ups. †HR (dronabinol/placebo) according to Cox regression analysis (losses to follow-up regarded as censored 
observations); sensitivity analysis (losses to follow-up regarded as progression events) resulted in HR 1·11 (0·86–1·44), 
p value=0·41. ‡Estimated between-group diﬀ erence (dronabinol–placebo) according to multilevel model. §Estimated 
OR according to logistic regression model (dronabinol/placebo). 
Table 3: Summary of main results
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prematurely discontinued trial treatment (ﬁ gure 1). A 
summary of the main results is shown in table 3.
Primary (ie, Cox regression) analysis showed no evidence 
of an eﬀ ect of age (p=0·36), disease type (p=0·12), sex 
(p=0·56), weight (p=0·11), or treatment (p=0·57; table 3) 
on time to conﬁ rmed EDSS score progression. The 
adjusted HR for ﬁ rst EDSS score progression event in 
patients randomly assigned to dronabinol compared with 
those assigned to placebo was 0·92 (95% CI 0·68–1·23; 
table 3). At trial completion, Kaplan-Meier estimates of the 
probability of EDSS score progression were 0·55 
(95% CI 0·46–0·63) in the dronabinol group, compared 
with 0·60 (0·44–0·71) in the placebo group (ﬁ gure 2). Of 
3812 assessments of EDSS score, 42 (1%) were by telephone 
(39 patients; 25 assigned to dronabinol and 14 assigned to 
placebo).
We noted evidence of some centre eﬀ ects (data not 
shown) and of an eﬀ ect of baseline EDSS score on time 
to conﬁ rmed progression. Prespeciﬁ ed subgroup 
analyses of time to EDSS score progression suggested a 
diﬀ erential eﬀ ect of treatment between participants with 
lower (4·0–5·5) and higher (6·0–6·5) baseline EDSS 
scores (ﬁ gure 3).
Results of sensitivity analysis showed that when we 
regarded losses to follow-up as progression events, rather 
than censored observations, the estimated HR for EDSS 
score progression changed to 1·11 (95% CI 0·86–1·44), 
but the estimated eﬀ ect of treatment remained non-
signiﬁ cant (p=0·41). This change in HR might be 
because the dronabinol group had a higher proportion of 
losses to follow-up for EDSS assessment (56 [79%] of 71) 
than did the placebo group (15 [21%] of 71) and represents 
a worst-case scenario in terms of patient deterioration 
and hence the potential beneﬁ t of dronabinol.
A multilevel model ﬁ tted to repeated measures of MSIS-
29-PHYS score showed no evidence of an eﬀ ect of 
treatment (estimated eﬀ ect –0·9 points, 95% CI –2·0 to 0·2; 
p=0·11), or of disease type, sex, weight, or centre (data not 
shown; p>0·05 for all).
We estimated that the MSIS-29-PHYS score reduced by 
a mean of 1·4 points (95% CI 0·3–2·5) for every 10 year 
increase in age (p=0·02). In both treatment groups, mean 
MSIS-29-PHYS score decreased from baseline to 
month 3, after which it tended to increase (ﬁ gure 4). With 
the exception of a small reduction in MSIS-29-PHYS 
score in patients with a baseline EDSS score of 5·0 
compared with those with a score of 4·0, MSIS-29-PHYS 
score tended to increase with increasing baseline EDSS 
score (data not shown). Results remained unchanged 
after removal of non-signiﬁ cant terms from the ﬁ tted 
model and under an alternative analysis based on 
comparison of treatment groups in terms of change from 
baseline to last valid observation.
Results of multilevel models showed little evidence of an 
eﬀ ect of treatment on MSFC, MSWS-12, or RMI (table 3).
Table 4 shows characteristics of the MRI substudy 
population. Dronabinol did not signiﬁ cantly aﬀ ect brain 
atrophy compared with placebo over the course of the 
study (estimated eﬀ ect –0·01%, 95% CI –0·26 to 0·24; 
p=0·94). However, atrophy did change signiﬁ cantly over 
Figure 2: Kaplan-Meier estimates of the probability of EDSS score progression
Only EDSS score progression events that were conﬁ rmed 6 months after the ﬁ rst observation were included in the 
Kaplan-Meier analysis; plot shows timings of ﬁ rst events, not 6 month conﬁ rmations. Numbers accompanying the 
numbers at risk in parentheses are the cumulative number of censored observations. +=patients who were lost to 
follow-up during the trial. ×=time of last follow-up in those patients who reached the end of the trial (ie, were 
followed up for 3 years) without progressing. EDSS=expanded disability status scale.
Figure 3: EDSS score progression by subgroup
Hazard ratio (unadjusted) of EDSS score progression in the dronabinol group compared with the placebo group. 
EDSS=expanded disability status scale. PPMS=primary progressive multiple sclerosis. SPMS=secondary progressive 
multiple sclerosis.
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Disease type
PPMS
SPMS
Weight (kg)
<60
60–80
>80
Age (years)
≤45
46–55
≥56
Total
p value
 1·28 (0·80–2·03)
0·94 (0·66–1·34)
1·63 (0·85–3·10)
1·15 (0·76–1·73)
0·52 (0·32–0·85)
1·08 (0·70–1·66)
1·08 (0·74–1·57)
0·98 (0·55–1·76)
1·01 (0·65–1·55)
1·15 (0·71–1·87)
1·32 (0·72–2·43)
0·71 (0·46–1·10)
1·46 (0·91–2·33)
1·06 (0·80–1·41)
201
292
129
254
110
191
302
99
215
179
94
203
196
493
0·30
0·74
0·14
0·51
0·01
0·74
0·69
0·96
0·98
0·57
0·36
0·13
0·11
0·66
0·3 0·4 0·5 0·6 0·7 0·8 0·9 1·0 1·2 1·4 1·6 1·8 2·0 2·2 2·5 3·0 3·5
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time (p<0·0001); using a ﬁ tted model, we estimated 
cumulative PBVC to be a mean of –0·58% at year 1, 
–1·20% at year 2, and –2·02% at year 3 (ﬁ gure 5).
We noted evidence of an eﬀ ect of baseline normalised 
brain volume (NBV) on atrophy: for a 100 unit reduction 
in baseline NBV, atrophy increased by an estimated 
mean of 0·21% (95% CI 0·08–0·34; p=0·003).
Treatment did not signiﬁ cantly aﬀ ect the occurrence of 
new or newly enlarging T2 lesions (estimated odds ratio 
[OR] 1·05, 95% CI 0·59–1·88; p=0·87) or new T1 lesions 
(0·89, 0·50–1·58; p=0·70).
Subgroup analysis of time to EDSS score progression in 
patients with a baseline EDSS score of 4·0–5·5 suggested 
a treatment eﬀ ect (HR 0·52, 95% CI 0·32–0·85; ﬁ gure 3) 
and led to a post-hoc analysis of progression in patients 
with this EDSS score, which provided some evidence of a 
potentially beneﬁ cial eﬀ ect of active treatment compared 
with placebo (p=0·01, log-rank test; appendix). However, 
time to EDSS score progression in patients with a baseline 
EDSS score of 6·0 and those with a score of 6·5 was not 
signiﬁ cantly aﬀ ected by dronabinol compared with 
placebo (EDSS score of 6·0, HR 1·15 [95% CI 0·76–1·73] 
and EDSS score of 6·5, HR 1·63 [0·85–3·10]).
Dronabinol did not signiﬁ cantly aﬀ ect atrophy in the 
subgroup of patients with a baseline EDSS score of 5·5 
or lower (estimated eﬀ ect –0·06%, 95% CI –0·42 to 0·29; 
p=0·73) or those with a baseline EDSS score of 6·0–6·5 
(0·01%, –0·26 to 0·28; p=0·95).
114 (35%) of 329 patients who received dronabinol had 
at least one serious AE compared with 46 (28%) of 
164 patients who received placebo, the most common 
serious AE being admission to hospital for multiple-
sclerosis-related events and infections. The number and 
nature of serious AEs reported did not signiﬁ cantly diﬀ er 
between groups (table 5).
Both groups had many non-serious AEs, consistent 
with the eﬀ ects of multiple sclerosis and the known 
safety proﬁ le of cannabinoids. The median number of 
events per participant in the dronabinol group was 
11 (IQR 7–17), compared with 10 (6–14) in the placebo 
group. Of those events judged to be either moderate or 
severe, the most frequent are documented in table 5.
Figure 4: Change in MSIS-29-PHYS score over time
Datapoints show mean MSIS-29-PHYS score; vertical lines show 95% CI. MSIS-29-PHYS=29-item multiple 
sclerosis impact scale, physical impact subscale. n=number of patients with total scores calculated at each visit. 
*If deterioration was noted at 36 months, a ﬁ nal follow-up visit was done at 42 months to conﬁ rm progression; if 
a patient went on to have an assessment at 42 months, data from this visit were used; if not, data from the 
assessment at 36 months were used.
Time (months)
0 3 6 12 18 24 30 36 or 42*
50
0
51
52
53
54
55
56
57
58
59
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n=326
n=290
n=287
n=280
n=269
n=263 n=258
n=250
n=162
n=155
n=148 n=143 n=141
n=136
n=136 n=137Dronabinol
Placebo
Dronabinol 
(n=182)
Placebo
(n=91)
All
(n=273)
Baseline age (years) 52·4 (7·3) 52·2 (8·1) 52·3 (7·6)
Baseline weight (kg) 74·3 (16·1) 75·7 (17·5) 74·8 (16·6)
Men 80 (44%) 31 (34%) 111 (41%)
Women 102 (56%) 60 (66%) 162 (59%)
Primary progressive MS 60 (33%) 38 (42%) 98 (36%)
Secondary progressive MS 122 (67%) 53 (58%) 175 (64%)
Baseline EDSS score (n per score)
4 14 (8%) 6 (7%) 20 (7%)
4·5 12 (7%) 5 (5%) 17 (6%)
5 12 (7%) 6 (7%) 18 (7%)
5·5 8 (4%) 3 (3%) 11 (4%)
6 95 (52%) 47 (52%) 142 (52%)
6·5 41 (23%) 24 (26%) 65 (24%)
Baseline EDSS score 6 (5·6–6) 6 (6–6·5) 6 (6–6)
Baseline normalised brain 
volume
1422 (91·0) 1417 (85·1) 1420 (88·9)
Not reported 24 (13·2) 8 (8·8) 32 (11·7)
Cumulative atrophy (%)
Year 1 –0·59% 
(0·95)
–0·60% 
(0·95)
–0·59% 
(0·95)
Not reported or excluded 28 (15%) 9 (9·9%) 37 (13·6%)
Year 2 –1·16% 
(1·33)
–1·18% 
(1·30)
–1·17% 
(1·31)
Not reported or excluded 44 (24%) 15 (16·5%) 59 (21·6%)
Year 3 –1·95% 
(1·51)
–1·82% 
(1·47)
–1·90% 
(1·49)
Not reported or excluded 58 (32%) 20 (22·0%) 78 (28·6%)
New or enlarging T1 lesions during follow-up
0 107 (59%) 57 (63%) 164 (60%)
1 24 (13%) 13 (14%) 37 (14%)
2 12 (7%) 7 (8%) 19 (7%)
3 5 (3%) 5 (5%) 10 (4%)
≥4 13 (7%) 3 (3%) 16 (6%)
Not reported or excluded 21 (12%) 6 (7%) 27 (10%)
New or enlarging T2 lesions during follow-up
0 101 (55%) 51 (56%) 152 (56%)
1 22 (12%) 16 (18%) 38 (14%)
2 11 (6%) 3 (3%) 14 (5%)
3 7 (4%) 4 (4%) 11 (4%)
≥4 20 (11%) 11 (12%) 31 (11%)
Not reported or excluded 21 (12%) 6 (7%) 27 (10%)
Data are mean (SD), n (%), and median (IQR). MS=multiple sclerosis. 
EDSS=expanded disability status scale.
Table 4: Characteristics of the MRI substudy population by treatment 
group and overall
See Online for appendix
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Discussion
No treatments have as yet shown clinical eﬃ  cacy in the 
modiﬁ cation of progressive multiple sclerosis in the 
absence of relapses (panel). Results of this study did not 
show an overall treatment eﬀ ect of oral dronabinol on 
clinical disease course in progressive multiple sclerosis, 
nor did dronabinol aﬀ ect the rate of brain atrophy.
Several factors might have reduced the chance of 
ﬁ nding any potential treatment eﬀ ect, particularly 
treatment discontinuation, loss to follow-up, and less 
overall progression than expected. Long-term studies in 
progressive neurological diseases are notoriously diﬃ  cult 
to undertake: loss to follow-up might hinder 
interpretation of results, and low event rates and 
discontinuation of study medication also decrease the 
power to detect a treatment eﬀ ect. Overall, loss to follow-
up in CUPID was around the level expected, but more 
attrition occurred in the dronabinol group. This coincided 
with a higher number of AEs than in the placebo group, 
which also largely accounted for premature treatment 
discontinuation, although no major safety concerns were 
reported. As in previous studies of cannabinoids, most 
AEs occurred during the dose titration period, but the 
high lipid solubility of cannabinoids means that long-
term build-up can occur some months after treatment 
initiation. Any future long-term studies to investigate 
disease-modifying eﬀ ects of cannabinoids should use 
lower doses to reduce the risk of AEs, which should 
increase compliance and reduce potential error in any 
intention-to-treat analysis.
Low progression rates make the identiﬁ cation of a 
treatment eﬀ ect less likely, and further work is necessary 
to establish optimum inclusion criteria for trials of 
progressive multiple sclerosis. Our study population was 
skewed towards the higher end of the EDSS score range 
(52% had a score of 6·0; 26% had a score of 6·5). Mean 
EDSS score at baseline was 5·9 (SD 0·69), higher than 
all other recent studies of treatments in progressive 
disease. Some studies have taken account of the slower 
progression rates in patients with higher EDSS scores by 
adjusting recruitment to ensure a lower overall mean 
EDSS score. The PROMiSe study18 was adjusted to 40% 
recruitment of patients with an EDSS score of 3·0–5·0, 
producing a mean EDSS score of 4·9 and yearly 
progression rate of 16% in patients with primary 
progressive multiple sclerosis, compared with 24% 
estimated in CUPID. Other outcome measures also did 
not show expected rates of progression. Although recent 
studies have tried to be more speciﬁ c about monitoring 
pretrial progression to fulﬁ l inclusion criteria, CUPID 
was designed to be a pragmatic study for people with 
progressive multiple sclerosis, testing some of the 
ﬁ ndings from the CAMS extension phase, which 
suggested that dronabinol might have an eﬀ ect on 
multiple sclerosis progression. Future studies should 
ensure that the population recruited has a high chance of 
progression.
Prespeciﬁ ed and exploratory subgroup analyses 
suggested that dronabinol might have a slight potentially 
beneﬁ cial eﬀ ect in terms of EDSS score progression and 
other outcome measures in less disabled patients 
(baseline EDSS score <6·0). Conversely, dronabinol 
might have a slight potentially negative eﬀ ect in patients 
with higher EDSS scores. One possible explanation for 
these ﬁ ndings is that cannabinoids have been shown to 
reduce muscle stiﬀ ness;1,19,20 although an antispasticity 
Figure 5: Cumulative PBVC over time
Datapoints show cumulative PBVC (%) measured at yearly MRI visits; vertical 
lines show 95% CI. n=number of patients with cumulative PBVC calculated at 
each visit. PBVC=percentage brain volume change.
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Dronabinol 
(n=329)
Placebo 
(n=164)
All 
(n=493)
p value*
Serious adverse events
Death 6 (1·8%) 1 (0·6%) 7 (1·4%) 0·43
Admission to hospital 106 (32%) 44 (27%) 150 (30%) 0·25
Life-threatening or important medical event 10 (3·0%) 4 (2·4%) 14 (2·8%) 1
At least one of the above 114 (35%) 46 (28%) 160 (32%) 0·15
Most common adverse events
Falls and injuries 101 (31%) 51 (31%) 152 (31%) 0·99
Mobility, balance, and coordination problems 108 (33%) 43 (26%) 151 (31%) 0·16
Infections (excluding urinary tract) 95 (29%) 47 (29%) 142 (29%) 0·96
Fatigue and tiredness 81 (25%) 38 (23%) 119 (24%) 0·81
Dizziness and lightheadedness 105 (32%) 12 (7%) 117 (24%) <0·0001
Muscle disorders (spasticity, stiﬀ ness, spasms, or tremor) 78 (24%) 38 (23%) 116 (24%) 0·98
Muscle disorders (weakness) 74 (22%) 32 (20%) 106 (22%) 0·52
Dissociative and thinking or perception disorders 98 (30%) 6 (4%) 104 (21%) <0·0001
Mood disorders (depression) 66 (20%) 26 (16%) 92 (19%) 0·31
Musculoskeletal pain and aches 49 (15%) 41 (25%) 90 (18%) 0·009
Constipation, diarrhoea, or faecal incontinence 56 (17%) 22 (13%) 78 (16%) 0·37
Joint disorders 47 (14%) 28 (17%) 75 (15%) 0·50
Urinary tract infections 44 (13%) 28 (17%) 72 (15%) 0·34
Data are number of patients who had at least one event of a given class (% per treatment group). *From Fisher’s exact 
tests, with no adjustments for multiple comparisons.
Table 5: Serious adverse events and most common adverse events
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eﬀ ect might improve function at lower levels of disability, 
if walking is compromised by weakness, dronabinol 
might reduce muscle tone to the point where muscle 
power becomes aﬀ ected and walking is more diﬃ  cult. 
This side-eﬀ ect is well known with agents such as 
baclofen. Distinguishing a symptomatic eﬀ ect from a 
disease-modifying eﬀ ect can be a diﬃ  cult task, although 
the fact that no eﬀ ect on brain atrophy was seen argues 
against a substantial neuroprotective eﬀ ect of 
cannabinoids in progressive multiple sclerosis.1,7,19,20
This independent study provides the largest dataset on 
cannabinoid exposure over time currently available. Most 
outcomes, both primary and secondary, did not provide 
any evidence for a treatment eﬀ ect with dronabinol. The 
suggestion of a potential eﬀ ect in lower disability groups 
might have relevance for inclusion criteria in future 
clinical trials in progressive multiple sclerosis. CUPID 
data, when used to calculate sample sizes for further 
studies recruiting patients with an EDSS score of 
4·0–5·5, suggest that a sample of around 375 participants 
would have 90% power to detect a diﬀ erence of around 
18% between dronabinol and placebo. In view of the 
shortage of treatments for multiple sclerosis progression, 
further trials in progressive multiple sclerosis focusing 
on patients whose disease seems most likely to progress 
are indicated.
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